Voy­ager's gene ther­a­py for Parkin­son's shows promise in ear­ly da­ta from small Phase Ib tri­al

Voy­ager Ther­a­peu­tics $VY­GR re­port­ed some good news from the front lines of its gene ther­a­py clin­i­cal tri­al in Parkin­son’s, show­ing the com­pa­ny’s drug might one day res­cue pa­tients from the in­evitable de­cline as­so­ci­at­ed with their re­sponse to lev­odopa.

Parkin­son’s, char­ac­ter­ized by low dopamine lev­els in the brain, pro­gress­es over time with the pa­tient ex­pe­ri­enc­ing a de­bil­i­tat­ing loss of mo­tor and non-mo­tor func­tions – with symp­toms like trem­bling, slow­ing of move­ments, and im­paired bal­ance. As the dis­ease pro­gress­es, these symp­toms be­come more se­vere, re­sult­ing in pe­ri­ods of de­creased func­tion in the pa­tient, al­so called “off” time. Thanks to ex­ces­sive dos­es of lev­odopa aimed at treat­ing the “off” time, some pa­tients ex­pe­ri­ence in­vol­un­tary move­ments, or dysk­i­ne­sia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER